If the Biogen CEO were truly ‘courageous,’ he would live with the Medicare decision

Someone needs to tell Michel Vounatsos that he suffers from a terrible case of tin ear syndrome.

At a time when many Americans are increasingly angry over the cost of medicines, the Biogen chief executive last June slapped a $56,000 price tag on its newly approved Alzheimer’s treatment.

Ever since, nothing but scandal has enveloped him and the company he runs. Moreover, he has further harmed an industry that often struggles — sometimes, for good reason — to convince the public it is on the side of the angels.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus in-depth analysis, newsletters, premium events, and networking platform access.

Already have an account? Log in

Already have an account? Log in

Individual plans

Group plans

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe

Log In